Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...

Explore Regulus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RGLS. Regulus Therapeutics Stock Shoots Higher After Positive Results From ...

Regulus (RGLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Also Read: Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ:RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...